The impact of a delay in initiating radiation therapy on prostate‐specific antigen outcome for patients with clinically localized prostate carcinoma
- 6 April 2005
- Vol. 103 (10), 2053-2059
- https://doi.org/10.1002/cncr.21050
Abstract
BACKGROUND To determine whether a delay in initiating external beam radiation therapy (RT) following diagnosis could impact prostate‐specific antigen (PSA) outcome for patients with localized prostate cancer, 460 patients, who received 3D conformal RT to a median dose of 70.4 Gy for clinically localized prostate cancer between 1992 and 2001, were studied. METHODS The primary endpoint was PSA failure (American Society for Therapeutic Radiology and Oncology definition). Estimates of PSA control were made using the Kaplan–Meier method. Delay was defined as the time between diagnosis and the start of RT. Risk groups were defined based on known predictors of PSA outcome, namely, baseline PSA level, clinical T‐category, Gleason score, and percentage of biopsy cores positive for tumor. Cox multivariate regression analysis was used to determine the ability of treatment delay to predict time to PSA failure after adjusting for the other known predictors. RESULTS Treatment delay independently predicted time to PSA failure following diagnosis for high‐risk (Adjusted Hazard Ratio = 1.08 per month; P = 0.029) but not low‐risk patients (P = 0.31). Patients with high‐risk disease (n = 240) had 5‐year estimates of PSA failure‐free survival of 55% versus 39% (Plog‐rank = 0.014) for those with delay < 2.5 months versus ≥ 2.5 months respectively. The median delay was 2.5 months. CONCLUSIONS Treatment delay adversely affected PSA outcome for high‐risk patients but not for low‐risk patients following RT. Cancer 2005. © 2005 American Cancer Society.Keywords
This publication has 16 references indexed in Scilit:
- Intermediate End Point for Prostate Cancer-Specific Mortality Following Salvage Hormonal Therapy for Prostate-Specific Antigen FailureJNCI Journal of the National Cancer Institute, 2004
- Prostate Cancer Radiotherapy Dose Response: An Update of the Fox Chase ExperienceJournal of Urology, 2004
- Dose escalation for localized prostate cancer: substantial benefit observed with 3D conformal therapyInternational Journal of Radiation Oncology*Biology*Physics, 2003
- Determinants of Prostate Cancer–Specific Survival After Radiation Therapy for Patients With Clinically Localized Prostate CancerJournal of Clinical Oncology, 2002
- Does waiting time for radiotherapy affect local control of T1N0M0 glottic laryngeal carcinoma?Clinical Otolaryngology, 2000
- The influence of delay in the initiation of definitive radiotherapy in carcinoma of the tonsillar regionInternational Journal of Radiation Oncology*Biology*Physics, 1998
- Does waiting time affect the outcome of larynx cancer treated by radiotherapy?Radiotherapy and Oncology, 1997
- Improved Survival in Patients with Locally Advanced Prostate Cancer Treated with Radiotherapy and GoserelinThe New England Journal of Medicine, 1997
- Waiting for radiotherapy in OntarioInternational Journal of Radiation Oncology*Biology*Physics, 1994
- Censoring distributions as a measure of follow‐up in survival analysisStatistics in Medicine, 1986